![Open Access](/resources/images/iconopenaccess.png)
The predictive value of β2‑MG and TGF‑β for elderly hypertensive nephropathy
- Authors:
- Published online on: February 14, 2019 https://doi.org/10.3892/etm.2019.7278
- Pages: 3065-3070
-
Copyright: © Cao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Abstract
Introduction
Hypertension is a common chronic disease (1), and its morbidity increases year by year with the development of society aging, the change of dietary structure and the gradual improvement of living standards, which threaten the life and health of the elderly (2). The morbidity of hypertensive nephropathy has also increased, and it is the most common and most serious complication of hypertension (3). If the glomeruluses are in a permanent state of high pressure, high infusion, and hyperfiltration caused by hypertension, the renal tubules and glomerular filtration membranes will be damaged and then result in hypertensive nephropathy (4,5). The early clinical manifestation of hypertensive renal injury generally is nocturia, but it is very difficult to attract patients' attention, and it usually shows normal during the routine examinations. However, generally speaking, the kidneys are already severely damaged when renal function shows abnormalities (6,7). Thus, the normality in the renal function indicators and urine protein of the patients with hypertension do not indicate that the kidneys are not pathologically damaged (8). So it is particularly important to seek the sensitive indicators for the diagnosis of renal injury of the patients with hypertension.
In recent years, research which uses β2-microglobulin (β2-MG) and transforming growth factor-β (TGF-β) on the diagnosis of hypertensive nephropathy has gradually increased (9–11). It is reported in the literature that β2-MG is a good indicator in the diagnosis of early hypertensive renal injury (12). It is a small molecular globulin that is reabsorbed by renal proximal convoluted tubules after being freely filtered through the glomerulus, and finally is degraded into amino acids by renal tubular endothelial cells. The increase of the level of β2-MG in the serum can reflect the impaired filtration function or increased filtration load of the glomerulus (13). Studies have shown that hypertensive nephropathy is closely related to TGF-β, which is highly expressed in hypertensive nephropathy and affects the development course of hypertensive nephropathy and the prognosis of patients (6). It is also reported in the literature that the main pathological changes of hypertensive nephropathy are renal interstitial fibrosis and glomerulosclerosis, and the main factor that regulates extracellular matrix deposition and stimulates the production of collagen is TGF-β (14,15). At the same time, TGF-β is a hematological indicator that can be detected conveniently and operated repeatedly.
Relative study of the combined application of β2-MG and TGF-β in the diagnosis of elderly hypertensive nephropathy has not been established, therefore, the aim of this study was to investigate the diagnostic value of β2-MG and TGF-β in elderly hypertensive nephropathy, and to provide some theoretical basises and references for the early clinical diagnosis, treatment and prognosis.
Materials and methods
General data
The clinical data of 56 patients, who were more than 60 years old, with hypertensive nephropathy, and admitted to Affiliated Hospital of Chengde Medical College (Chengde, China) from December 2015 to December 2017, were retrospectively analyzed and the clinical data were used as the study group, including 34 males and 22 females. The systolic pressure of all the patients was 140 mmHg or more and the diastolic pressure of them was 90 mmHg or more on average, and the 24 h urine protein of the patients in the study group was more than 30 mg/l or any urine protein was more than 37 mg/l, moreover, the clinical data of 50 patients, who were more than 60 years old, with hypertension, but did not have nephropathy, were selected as the control group, including 29 males and 21 females. There were no significant difference in each indicator of the general data of the patients in the two groups (P>0.05). Some physiological conditions of the patients were excluded, including the insufficiency of the cardiac and hepatic functions, the incompletion of clinical data, the existence of cancer, coagulopathy and severe metabolic diseases as well as other renal organic lesions.
This study was approved by the Εthics Committee of Affiliated Hospital of Chengde Medical College. Patients who participated in this research had complete clinical data. The signed informed consents were obtained from the patients or the guardians. The general data of the selected persons are shown in Table I.
Detection methods
The fasting venous blood of the patients was taken in the morning (33 ml in a vacuum blood collection tube). The blood was naturally agglutinated for 10 to 20 min at indoor temperature and centrifuged at 3,000 × g for 5 min at 4°C and the supernatant was taken. The processes of sample loading were as follows: Firstly, 100 µl of the sample diluent was added into the blank well, and then 100 µl of the sample to be tested was respectively added into the standard well and the sample well, and 100 µl of the test solution was added into each well after the sample to be tested was drained and dried, next, the test solution was incubated for 1 h at 37°C, then it was drained and dried again, and rinsed 3 times using PBS, after being dried, 100 µl of another test solution was added, then the mixed solution was incubated for 1 h at 37°C and was drained and dried, and rinsed 3 times using PBS, then 90 µl of the substrate solution was added, and the color was developed in the dark at 37°C, finally 50 µl of the stop solution was added to terminate the translation. ELISA and Multiskan Spectrum Microplate Spectrophotometer (SPECTROstar® Omega; Boqi Biotechnology Co., Ltd.) were used to detect β2-MG (QY-MB12035; Shanghai Qiaoyu Biotechnology Co., Ltd., Shanghai, China) and TGF-β (YM-E3369W; Shanghai Yunmai Biotechnology Co., Ltd., Shanghai, China) and the serum of the patients was measured, as OD value at 450 nm wavelength. All the operations were strictly carried out according to the specifications.
Statistical analysis
The analysis was performed by using SPSS 19.0 (SPSS, Inc., Chicago, IL, USA) statistical software. Chi-square test was used for enumeration data and t-test was used for measurement data. Pearsons analysis was used for correlation analysis. The diagnostic value of β2-MG, TGF-β and their combined application were analyzed, using ROC curve. P<0.05 was considered to indicate a statistically significant difference.
Results
The expression levels of β2-MG and TGF-β in the serum of the patients in the two groups
The expression levels of β2-MG and TGF-β in the serum of the patients in the study group (2.86±1.18 mg/l and 73.46±15.63 µg/l) were significantly higher than those in the control group (1.87±0.65 mg/l and 52.89±13.58 µg/l), the difference was statistically significant (P<0.001; Fig. 1 and Table II).
There was a positive correlation between the expression levels of β2-MG and TGF-β in the serum of the patients who had hypertensive nephropathy (r=0.619, P<0.001; Fig. 2).
The sensitivity and specificity of β2-MG and TGF-β in the diagnosis of hypertensive nephropathy
The analysis result of the ROC curve of β2-MG in the diagnosis of hypertensive nephropathy showed that the AUC of β2-MG in the diagnosis of hypertensive nephropathy was 0.786; the 95% confidence interval was from 0.699 to 0.871, and the cut-off value was 2.480; there were 33 positive cases in the study group and 4 in the control group; the sensitivity was 58.93%, and the specificity was 92.00%.
The analysis of the ROC curve of TGF-β in the diagnosis of hypertensive nephropathy showed that the AUC of TGF-β in the diagnosis of hypertensive nephropathy was 0.793; the 95% confidence interval was from 0.709 to 0.877, and the cut-off value was 59.330; there were 39 positive cases in the study group and 10 in the control group; the sensitivity was 69.64%, and the specificity was 80.00%.
The analysis result of the ROC curve of the combined application of β2-MG and TGF-β in the diagnosis of hypertensive nephropathy showed that the AUC of the combined application of β2-MG and TGF-β in the diagnosis of hypertensive nephropathy was 0.860; the 95% confidence interval was from 0.791 to 0.928, and the cut-off value was 0.303; there were 53 positive cases in the study group and 17 in the control group; the sensitivity was 94.64%, and the specificity was 66.00% (Fig. 3 and Table III).
![]() | Table III.The sensitivity and specificity of β2-MG, TGF-β in the diagnosis of hypertensive nephropathy. |
Discussion
Hypertension is a disease that is affected by environmental and genetic factors (16). According to the statistics, there are approximately 1.1 billion adult patients with hypertension in the world, among which approximately 700 million adult patients with hypertension are in the developing countries and approximately 400 million adult patients with hypertension are in the developed countries (17). In the state of persistent hypertension, the organism will suffer from arteriolosclerosis, however, the impairment of the kidney is particularly obvious when compared with all the visceral organs. The regulatory functions of the kidney will be weaken by a state of high pressure, high filtration, and high perfusion, which will lead to the disequilibrium of hemodynamics and the abnormity of functions in the kidney (18,19). According to the reports in the literature, generally β2-MG is rarely found in the blood and urine of healthy people, and the resultant rate is stable, and there is no significant difference in its changes between the morning and evening. Therefore, the evaluation of the functions of renal tubular and glomerulus will be more stable and accurate when using β2-MG as indicator (20). It is also found in other studies that TGF-β is overexpressed in diabetic hypertensive nephropathy and is involved in the pathogenesis of diabetic hypertensive nephropathy (21).
This study showed that the expression levels of β2-MG and TGF-β in the serum of the patients in the study group were significantly higher than those in the control group, and the difference was statistically significant (P<0.001). Study has shown that the rise of β2-MG in the serum indicates that the filtration function of glomerulus is damaged or is overloaded (22). TGF-β plays a major role in many renal diseases and the formation of hypertensive renal scars, and is an early indicator of hypertensive benign renal disease (23). The study of Rouse et al showed that the expression level of β2-MG in the serum of the patients who had hypertensive nephropathy was significantly higher than that of patients with only hypertension (6). The study of Kurts et al showed that the expression level of TGF-β in the serum of the patients with hypertensive nephropathy was significantly higher than that of patients who had hypertension, but did not have renal disease (24). The results of these studies were consistent with our findings. There was a positive correlation between the expression levels of β2-MG and TGF-β in the serum of the patients with hypertensive nephropathy (r=0.619, P<0.001). At present, no similar literature has been found to support the findings, but the results of our study demonstrated that if the expression levels of β2-MG and TGF-β in the serum of the patients increased, the impairment of renal functions is most likely to occur. The combined application of the two in the diagnosis could help to detect the occurrence of hypertensive nephropathy.
The analysis of the ROC curve of β2-MG in the diagnosis of hypertensive nephropathy showed that the AUC of β2-MG in the diagnosis of hypertensive nephropathy was 0.786; the 95% confidence interval was from 0.699 to 0.871, and the cut-off value was 2.480; there were 33 positive cases in the study group, the sensitivity was 58.93%, and the specificity was 92.00%. The result of the ROC curve of TGF-β in the diagnosis of hypertensive nephropathy showed that the AUC of TGF-β in the diagnosis of hypertensive nephropathy was 0.793; the 95% confidence interval was from 0.709 to 0.877, and the cut-off value was 59.330; there were 39 positive cases in the study group, the sensitivity was 69.64%, and the specificity was 80.00%. The result of the ROC curve of the combined application of β2-MG and TGF-β in the diagnosis of hypertensive nephropathy showed that the AUC of the combined application of β2-MG and TGF-β in the diagnosis of hypertensive nephropathy was 0.860; the 95% confidence interval was from 0.791 to 0.928, and the cut-off value was 0.303; there were 53 positive cases in the study group, the sensitivity was 94.64%, and the specificity was 66.00%. This indicated that TGF-β was not a specific indicator in the diagnosis of hypertensive nephropathy, but it still had screening value. The sensitivity of β2-MG in the diagnosis of hypertensive nephropathy was low, but the specificity was good. The sensitivity of the combined application of β2-MG and TGF-β in the diagnosis of hypertensive nephropathy was high, but the specificity was poor, which provided a more effective and comprehensive diagnostic basis for hypertensive nephropathy.
In summary, β2-MG and TGF-β were highly expressed in the patients with hypertensive nephropathy, and the expression levels of β2-MG and TGF-β were positively correlated (r=0.619, P<0.001). The sensitivity of the combined application of β2-MG and TGF-β was highest in the diagnosis of hypertensive nephropathy, but the specificity was worst. Therefore, the combined application of β2-MG and TGF-β in the diagnosis of hypertensive nephropathy could reduce or even avoid the missed diagnosis caused by single detection. The two indicators complemented and confirmed each other, which had a great significance for improving the positive diagnosis rate of hypertensive nephropathy.
Acknowledgements
Not applicable.
Funding
No funding was received.
Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Authors' contributions
JC wrote the manuscript. JC, RH and CZ performed ELISA. JL and KZ collected and analyzed the general data of patients. HJ, YF and YW were responsible for statistical analysis. All authors read and approved the final manuscript.
Ethics approval and consent to participate
This study was approved by the Εthics Committee of Affiliated Hospital of Chengde Medical College (Chengde, China). Patients who participated in this research had complete clinical data. The signed informed consents were obtained from the patients or the guardians.
Patient consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
References
James PA, Oparil S, Carter BL, Cushman WC, Dennison -Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, et al: 2014 evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 311:507–520. 2014. View Article : Google Scholar : PubMed/NCBI | |
Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK and He J: Global burden of hypertension: Analysis of worldwide data. Lancet. 365:217–223. 2005. View Article : Google Scholar : PubMed/NCBI | |
Hart PD and Bakris GL: Hypertensive nephropathy: Prevention and treatment recommendations. Expert Opin Pharmacother. 11:2675–2686. 2010. View Article : Google Scholar : PubMed/NCBI | |
Christiansen RE, Tenstad O, Leh S and Iversen BM: Glomerular charge selectivity is impaired in hypertensive nephropathy. Nephrol Dial Transplant. 19:1083–1091. 2004. View Article : Google Scholar : PubMed/NCBI | |
Fauvel JP and Laville M: Hypertensive nephropathy: A growing cause of renal insufficiency. Presse Med. 30:81–86. 2001.(In French). PubMed/NCBI | |
Rouse RL, Stewart SR, Thompson KL and Zhang J: Kidney injury biomarkers in hypertensive, diabetic, and nephropathy rat models treated with contrast media. Toxicol Pathol. 41:662–680. 2013. View Article : Google Scholar : PubMed/NCBI | |
Mahajan A, Simoni J, Sheather SJ, Broglio KR, Rajab MH and Wesson DE: Daily oral sodium bicarbonate preserves glomerular filtration rate by slowing its decline in early hypertensive nephropathy. Kidney Int. 78:303–309. 2010. View Article : Google Scholar : PubMed/NCBI | |
Tylicki L and Rutkowski B: Hypertensive nephropathy: pathogenesis, diagnosis and treatment. Pol Merkuriusz Lek. 14:168–173. 2003.(In Polish). | |
Aksun SA, Ozmen D, Ozmen B, Parildar Z, Mutaf I, Turgan N, Habif S, Kumanlioğluc K and Bayindir O: Beta2-microglobulin and cystatin C in type 2 diabetes: Assessment of diabetic nephropathy. Exp Clin Endocrinol Diabetes. 112:195–200. 2004. View Article : Google Scholar : PubMed/NCBI | |
Chen H and Li H: Clinical implication of cystatin C and β2-microglobulin in early detection of diabetic nephropathy. Clin Lab. 63:241–247. 2017. View Article : Google Scholar : PubMed/NCBI | |
Nozue T, Michishita I and Mizuguchi I: Predictive value of serum cystatin C, β2-microglobulin, and urinary liver-type fatty acid-binding protein on the development of contrast-induced nephropathy. Cardiovasc Interv Ther. 25:85–90. 2010. View Article : Google Scholar : PubMed/NCBI | |
Kurashige T, Takahashi T, Yamazaki Y, Nagano Y, Kondo K, Nakamura T, Yamawaki T, Tsuburaya R, Hayashi YK, Nonaka I, et al: Elevated urinary β2 microglobulin in the first identified Japanese family afflicted by X-linked myopathy with excessive autophagy. Neuromuscul Disord. 23:911–916. 2013. View Article : Google Scholar : PubMed/NCBI | |
Stakhova TIu, Shcherbak AV, Kozlovskaia LV, Taranova MV and Balkarov IM: Clinical value of the determination of markers for endothelial dysfunction (endothelin-1, microalbuminuria) and tubulointerstitial tissue lesion (β2-microglobulin, monocyte chemotactic protein-1) in hypertensive patients with uric acid metabolic disorders. Ter Arkh. 86:45–51. 2014.(In Russian). PubMed/NCBI | |
Liu GX, Li YQ, Huang XR, Wei LH, Zhang Y, Feng M, Meng XM, Chen HY, Shi YJ and Lan HY: Smad7 inhibits AngII-mediated hypertensive nephropathy in a mouse model of hypertension. Clin Sci. 127:195–208. 2014. View Article : Google Scholar : PubMed/NCBI | |
Liu GX, Li YQ, Huang XR, Wei L, Chen HY, Shi YJ, Heuchel RL and Lan HY: Disruption of Smad7 promotes ANG II-mediated renal inflammation and fibrosis via Sp1-TGF-β/Smad3-NFκB-dependent mechanisms in mice. PLoS One. 8:e535732013. View Article : Google Scholar : PubMed/NCBI | |
Klingbeil AU, Schneider M, Martus P, Messerli FH and Schmieder RE: A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med. 115:41–46. 2003. View Article : Google Scholar : PubMed/NCBI | |
Staessen JA, Wang J, Bianchi G and Birkenhäger WH: Essential hypertension. Lancet. 361:1629–1641. 2003. View Article : Google Scholar : PubMed/NCBI | |
Schillaci G, Pirro M, Mannarino MR, Pucci G, Savarese G, Franklin SS and Mannarino E: Relation between renal function within the normal range and central and peripheral arterial stiffness in hypertension. Hypertension. 48:616–621. 2006. View Article : Google Scholar : PubMed/NCBI | |
Leoncini G, Viazzi F, Conti N, Baratto E, Tomolillo C, Bezante GP, Deferrari G and Pontremoli R: Renal and cardiac abnormalities in primary hypertension. J Hypertens. 27:1064–1073. 2009. View Article : Google Scholar : PubMed/NCBI | |
Shin JR, Kim SM, Yoo JS, Park JY, Kim SK, Cho JH, Jeong KH, Lee TW and Ihm CG: Urinary excretion of β2-microglobulin as a prognostic marker in immunoglobulin A nephropathy. Korean J Intern Med. 29:334–340. 2014. View Article : Google Scholar : PubMed/NCBI | |
Mohamed RH, Abdel-Aziz HR, Abd El Motteleb DM and Abd El-Aziz TA: Effect of RAS inhibition on TGF-β, renal function and structure in experimentally induced diabetic hypertensive nephropathy rats. Biomed Pharmacother. 67:209–214. 2013. View Article : Google Scholar : PubMed/NCBI | |
Dieterle F, Perentes E, Cordier A, Roth DR, Verdes P, Grenet O, Pantano S, Moulin P, Wahl D, Mahl A, et al: Urinary clusterin, cystatin C, beta2-microglobulin and total protein as markers to detect drug-induced kidney injury. Nat Biotechnol. 28:463–469. 2010. View Article : Google Scholar : PubMed/NCBI | |
Bicik Z, Gönen S, Bahçebasi T, Reis K, Arinsoy T and Sindel S: Role of transforming growth factor-β2 in, and apossible transforming growth factor-β 2 gene polymorphism as a marker of, renal dysfunction in essential hypertension: A study in Turkish patients. Curr Ther Res Clin Exp. 66:266–278. 2005. View Article : Google Scholar : PubMed/NCBI | |
Kurts C, Panzer U, Anders HJ and Rees AJ: The immune system and kidney disease: Basic concepts and clinical implications. Nat Rev Immunol. 13:738–753. 2013. View Article : Google Scholar : PubMed/NCBI |